CN103012248B - Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug - Google Patents

Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug Download PDF

Info

Publication number
CN103012248B
CN103012248B CN201310011060.9A CN201310011060A CN103012248B CN 103012248 B CN103012248 B CN 103012248B CN 201310011060 A CN201310011060 A CN 201310011060A CN 103012248 B CN103012248 B CN 103012248B
Authority
CN
China
Prior art keywords
cancer
amino
compound
trimethoxyphenyl
ethene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201310011060.9A
Other languages
Chinese (zh)
Other versions
CN103012248A (en
Inventor
王建平
王建国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Dade Pharmaceutical Group Co Ltd
Original Assignee
Zhejiang Dade Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Dade Pharmaceutical Group Co Ltd filed Critical Zhejiang Dade Pharmaceutical Group Co Ltd
Priority to CN201310011060.9A priority Critical patent/CN103012248B/en
Publication of CN103012248A publication Critical patent/CN103012248A/en
Priority to PCT/CN2014/070286 priority patent/WO2014108066A1/en
Application granted granted Critical
Publication of CN103012248B publication Critical patent/CN103012248B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The invention discloses a compound which is shown as a formula (I) and used for inhibiting generation of tumour neovascularization as well as officinal salt or a configurational isomer thereof, wherein substituent groups R1, R2 and R3 are defined in the specification. The invention also discloses a preparation method of the compound in the formula (I), a pharmaceutical composition and an application of the compound as a microtubulin inhibitor in the aspect of inhibiting the tumour neovascularization, especially an application as an oral preparation.

Description

Amino combretastatin derivative synthetic and as the application of oral antitumor drug
Technical field
The invention belongs to medical technical field, relate to a series of Combretastatin (Combretastatin) A4 derivative and preparation method thereof, and in the purposes of preparing in Antitubulin.
Background technology
Combretastatins series compound extracts to separate at first and obtains from the Combretum caffrum trunk of South Africa.It has anti-tumor activity, can directly act on endotheliocyte, the endothelial cell apoptosis of induction propagation, thus suppress tumor neovasculature generation, reach the object of tumors destroyed.Combretastatins series compound has cis stilbene structure.Wherein combretastatin A-4[CA-4, Combretastatin, cis-1-(3,4,5-trimethoxy) phenyl-2-(3 '-hydroxyl-4 '-methoxyl group) phenyl ethene] there is the strongest inhibition microtubule polymerization effect (Pettit G R, etal.J.Med.Chem (1995) 38 1666-1672).Recently, because CA-4 is as tumor vascular targeting reagent, demonstrates it and block tumor vascular good characteristic (Thorpe PE.Clin Cancer Res.2004Jan 15,10 (2): 415-27; West CM, Price P.Anticancer Drugs.2004 Mar, 15 (3): 179-87; Young SL, Chaplin DJ.Expert Opin Investig Drugs.2004Sep, 13 (9): 1171-82.).U.S. Oxigene, Inc. company as anti-cancer agent, has entered the clinical study of III phase with CA-4.The people such as the T.Hatanaka of Japanese Ajincomoto Co., Inc (Ajinomoto Co.) in 1997 find the hydroxyl of 3 of CA-4 ' position to be transformed into amino, and its antitumour activity improves (USP5674906) greatly.
But Combretastatins series compound water-soluble very poor, is very restricted its clinical application.And the hydroxyl of 3 of CA-4 ' position is transformed into after amino, at present common CA-4 is transformed into its phosphatic method inapplicable.Although Japanese Ajincomoto Co., Inc modifies amino CA-4 with amino acid, increase that it is water-soluble, becoming injection can use cancer patient.But its using method still has inconvenience.Therefore, the present invention will provide a kind of new amino CA-4 derivative, and this compound absorbs by digestive tube, and arrives the each position of whole body by blood-transmitted, various tumours is had to certain curative effect, especially liver cancer and colorectal carcinoma.
Summary of the invention
The invention provides a kind of compound or its pharmacy acceptable salt that logical formula I represents that contain below:
(Ⅰ)
Wherein
R 1independently selected from C 1-C 3alkyl, haloalkyl;
R 2independently selected from hydrogen, methyl, ethyl, halogen;
R 3be can be optionally substituted contain one or more heteroatomic heterocycles or Heterocyclylalkyl, wherein having a heteroatoms at least is N.
In formula I compound of the present invention, preferably there is general formula II (a) or II (b) compound:
Ⅱa
Ⅱb
Wherein
R 1independently selected from C 1-C 3alkyl, haloalkyl;
R 2independently selected from hydrogen, methyl, ethyl, halogen;
R 4independently selected from hydrogen, C 1-C 3alkyl, haloalkyl, cycloalkyl, aryl, heterocyclic aryl, Heterocyclylalkyl, alkyloyl, carbalkoxy;
R 5independently selected from hydrogen, halogen, alkyl, cycloalkyl, alkoxyl group, thiazolinyl, alkynyl, hydroxyl, sulfydryl, amino, nitro, cyano group, NR ar b, NR dc (O) R c, C (O) NR ar b, S (O) 2nR ar b, NR ds (O) 2r c, NR d(CH 2) nr c, (CH 2) nnR ar b, NHC (O) NH R c, (CH 2) nnHC (O) R c, NHC (NH) R c;
R a, R brespectively independently selected from hydrogen, alkyl, cycloalkyl, or can form heterocycle or the Heterocyclylalkyl of one 5,6 or 7 yuan with N, O, S atom;
R cindependently selected from alkyl, cycloalkyl, aryl, heterocyclic aryl, Heterocyclylalkyl;
R dindependently selected from hydrogen, alkyl, cycloalkyl, aryl, heterocyclic aryl;
Above-described alkyl, cycloalkyl, alkoxyl group, thiazolinyl, alkynyl, heterocyclic radical, Heterocyclylalkyl can be replaced by following any one or more groups: halogen, amino, alkylamino, dialkylamine, acid amides, aryl, heterocyclic radical, nitro, cyano group, carboxyl, carbalkoxy, hydroxyl, alkoxyl group, acyloxy,=O ,=S ,=NH.
Formula I compound of the present invention or its pharmacy acceptable salt, wherein said compound more preferably from:
(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-methyl piperidine-4-formyl radical) amino-4-ethoxyl phenenyl) ethene;
(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-methyl piperidine-4-formyl radical) amino-4-methoxyl phenyl) ethene;
(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-methyl piperidine-4-formyl radical) amino-4-difluoro-methoxy phenyl) ethene;
(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-methyl piperidine-4-formyl radical) amino-4-trifluoro ethoxy phenyl) ethene;
(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-hydroxymethyl piperidine-4-formyl radical) amino-4-methoxyl phenyl) ethene;
(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(2-pyrryl piperidines-4-formyl radical)) amino-4-methoxyl phenyl) ethene;
(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(pyridine-3-formyl radical) amino-4-methoxyl phenyl) ethene;
(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(2-kharophen pyridine-5-formyl radical) amino-4-methoxyl phenyl) ethene;
(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(2-5-flumethiazine-5-formyl radical)) amino-4-methoxyl phenyl) ethene;
(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(2-fluorine pyridine-5-formyl radical) amino-4-methoxyl phenyl) ethene;
(Z) the fluoro-1-of-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-methyl piperidine-4-formyl radical) amino-4-methoxyl phenyl) ethene;
(Z)-1-methyl isophthalic acid-(3,4,5-trimethoxyphenyl)-2-(3-(N-methyl piperidine-4-formyl radical) amino-4-methoxyl phenyl) ethene.
Pharmaceutically acceptable salt of formula I compound of the present invention, or containing at least one alkaline salt forming group, with the acid of its salify can be mineral acid or the organic acid of pharmaceutically commonly using, comprise mineral acid: hydrochloric acid, sulfuric acid, phosphoric acid; Organic carboxyl acid: acetic acid, propionic acid, trifluoroacetic acid, oxyacetic acid, succsinic acid, toxilic acid, fumaric acid, oxysuccinic acid, tartrate, citric acid, oxalic acid, various natural or synthetic amino acid, phenylformic acid, Whitfield's ointment, 4-ASA, amygdalic acid, styracin, nicotinic acid, γ-picolinic acid; Organic sulfonic acid: methylsulfonic acid, trifluoromethanesulfonic acid, ethyl sulfonic acid, 2-ethylenehydrinsulfonic acid, Phenylsulfonic acid, tosic acid, 2-naphthene sulfonic acid.In the time there is multiple basic group, can generate polyacid additive salt.
Compound of the present invention and pharmacy acceptable salt also comprise the form of solvate or hydrate.In general, the form of solvate or hydrate and form non-solvated or non-hydrated are equal to, and contain in the lump within the scope of the invention.Likely there is polycrystal or unbodied form in some compound in the present invention.Generally speaking, all physical form have equal purposes, and contain within the scope of the invention.
All steric isomers of the compounds of this invention that is form of mixtures or is pure form are contained in the present invention.The definition of the compounds of this invention comprises all possible steric isomer and composition thereof.It comprises racemic form and the optical isomer with given activity separating very particularly.Racemic form can split by physical method, and described physical method is such as diastereomer derivative being carried out to fractional crystallization, separation or separating by chiral column chromatogram.Can follow crystallization and obtain independent optical isomer from racemic modification by for example optical activity acid form salify of ordinary method.
In addition, the present invention also provides the method for synthetic formula I compound.Its technological process is as follows:
Ⅱa Ⅱb
Synthetic method of the present invention obtains corresponding microcosmic salt by the bromo of compound VII, after reacting with triphenylphosphine, then microcosmic salt is reacted to the toluylene structure (IV) that obtains cis by wittig with compound VIII.Toluylene becomes amino as reductive agent by the nitroreduction in structure with samarium metal powder with dibromo dioctyl dipyridyl, has just obtained amino compete A-4 (III).Then taking amino compete A-4 as raw material, (b), last and sour salify obtains final product for structure II a or II to connect into acid amides with pyridine carboxylic acid or piperidine carboxylic acid by the method for acyl chlorides or active ester.
The invention still further relates to the pharmaceutical composition of acceptable carrier in the formula I compound that comprises significant quantity and pharmacology, that said composition is applicable to is local, in intestines or intestines outside administration, can be inorganic or organic, solid-state or liquid.For oral, especially with tablet or capsule.This tablet or capsule comprise activeconstituents and thinner (as lactose, glucose, sucrose, mannitol, sorbyl alcohol, Mierocrystalline cellulose, glycerol), lubricant (as talcum, stearate), polyoxyethylene glycol.Tablet also can comprise tackiness agent, starch, gelatin, methylcellulose gum, Xylo-Mucine and/or polyvinylpyrrolidone, also can comprise disintegrator (as starch, agar, alginic acid and salt thereof), effervescent mixture, or sorbent material if desired, dyestuff, seasonings, sweetener.These compositions can also administered parenterally form or be suitable for the form of injection.The preferred isotonic aqueous solution of this type of formulation or emulsion, as in the case of the lyophilised compositions being only made up of activeconstituents and a kind of carrier (as N.F,USP MANNITOL), this type of solution can be prepared before use.These pharmaceutical compositions can be aseptic, or comprise vehicle, or the salt of solubilizing agent, adjusting osmotic pressure.
The invention still further relates to the application in the medicine of the disease that formula I compound causes at the improper new vessel of preparation treatment.The disease that improper new vessel causes comprises various tumours, mainly contains: lung cancer, small cell lung cancer, liver cancer, carcinoma of the pancreas, cancer of the stomach, osteocarcinoma, esophagus cancer, mastocarcinoma, kidney, cholangiocarcinoma, prostate cancer, carcinoma of testis, colorectal carcinoma, ovarian cancer, bladder cancer, cervical cancer, bronchogenic carcinoma, melanoma, gland cancer, syringocarcinoma, papillary carcinoma, papillary carcinoma, squamous cell carcinoma, rodent cancer, adenocarcinoma cystic, glioma, astrocytoma, medulloblastoma, neuroblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, oligodendroglioma, meningioma, neurofibroma, fibrosarcoma, fibroblastoma, fibroma, myxosarcoma, myxocystoma, lipoma, lipoadenoma, chondrosarcoma, chondroma, chondromyoma, chordoma, chorioadenoma, villous vessels knurl, chorioepithelium knurl, chorioblastoma, osteosarcoma, osteoblastoma, osteoclastoma, osteochondrofibroma, osteochondrosarcoma, thigh cystoma, osteodentinoma, osteofibroma, the fibrosarcoma of bone, vascular tumor, angiosarcoma, lymphangiosarcoma, lymphangioma, lymphoma, endothelioma, synovioma, synovial sarcoma, mesothelioma, mesocytoma, ewing's tumor, leiomyoma, leiomyosarcoma, rhabdomyoma, rhabdosarcoma, kemia, acute myelogenous leukemia, chronic leukemia, polycyth(a)emia, multiple myeloma.
The disease that improper new vessel causes also comprises: rheumatic arthritis, diabetic retinopathy, retinopathy of prematurity, retinal vein occlusion, psoriasis, acne erythematosa, kaposi's sarcoma, specific reaction keratitis, epidemic keratoconjunctivitis, neovascular glaucoma, bacterial canker, mycotic ulcer, herpes-ness progenitalis infection, zoster infects, protozoal infections, mycobacterium infects, polyarteritis, sarcoid, scleritis, flush, the dry sacroiliitis syndromes of dry eye, systemic lupus erythematosus, AIDS, syphilis.
The invention still further relates to formula I compound in the application of preparing in tubulin aggregation inhibitor.
The present invention also provides a kind of zooperal method, can verify by this method compound (I) absorption in animal body and the inhibition ability to tumour.
Embodiment
To describe exemplary of the present invention below in detail.But these embodiments only for the purpose of illustration, are not intended to limit the scope of the invention.
It is below the definition of the term that can use in this manual.Except as otherwise noted, the original definition that this patent provides with regard to group or term is applicable to described group or the term in the whole text at specification sheets, uses separately or uses as the part of another group no matter be.
Term " alkyl " refers to unsubstituted alkyl straight chain or side chain, it has 1-20 carbon atom, preferably 1-6 carbon atom, refers in particular to methyl, ethyl, propyl group (comprising n-propyl and sec.-propyl), butyl (comprising normal-butyl, isobutyl-, the tertiary butyl) etc.
Term " thiazolinyl " refers to the alkyl with one or more carbon-carbon double bonds, as vinyl, propenyl, 1,3-butadiene, maleic, anti-butylene etc.
Term " alkynyl " refers to the alkyl with multiple carbon carbon triple bonds, as ethynyl, proyl etc.
Term " halogen " or " halo " refer to fluorine (fluoro), chlorine (chloro), bromine (bromo), iodine (iodo).
Term " aryl " refers to the aromatic hydrocarbons of monocycle or many rings, such as benzene, naphthalene, anthracene, phenanthrene etc.
Term " heterocyclic aryl " refers to the aromatic series ring-type group of optional replacement, wherein at least contains a carbon atom and is replaced by other heteroatoms, and heteroatoms comprises nitrogen, oxygen, sulphur.This nitrogen and sulfur heteroatom also can be optionally oxidized, and nitrogen heteroatom also can be optionally quaternized.This heterocyclic group can connect at any heteroatoms or carbon atom place.Preferred heterocyclic aryl includes but not limited to, pyridine, pyrazine, pyrimidine, pyridazine, triazine, furans, thiophene, imidazoles, triazole, tetrazolium, thiazole, isothiazole, pyrroles, pyrazoles, oxazole, isoxazole, cumarone, benzothiazole, thionaphthene, indoles, quinoline, isoquinoline 99.9, purine, carbazole, benzoglyoxaline, pyrrolopyridine, pyrrolopyrimidine etc.
Term " cycloalkyl " refers to the carbocyclic ring of non-aromatic, comprises monocycle, condensed ring or volution.Cycloalkyl also comprises the ring that has one or more aromatic nucleus and condense (having a common key), has the cycloalkyl that one or more aromatic nucleus condense to be connected with other groups by aromatic nucleus or non-aromatic ring part.
Term " Heterocyclylalkyl " refers to nonaromatic heterocycles, and wherein one or more become annular atoms is heteroatoms, as oxygen, nitrogen, sulphur atom.Heterocyclylalkyl can comprise monocycle or many ring (if any 2,3,4 fused rings), volution.Preferred Heterocyclylalkyl comprises aziridine, azetidine, tetrahydrofuran (THF), tetramethylene sulfide, tetramethyleneimine, oxazolidine, thiazolidine, isothiazolidine, imidazolidine, pyrazolidine, morpholine, thiomorpholine, piperazine, piperidines etc.Heterocyclylalkyl also comprises having the heterocycle that one or more aromatic nucleus condense, for example 2, and 3-Dihydrobenzofuranes, 1,3-benzo dioxolane, phendioxin, 4-diox, benzenedicarboxamide etc.Having the Heterocyclylalkyl that one or more aromatic nucleus condense can be connected with other group by aromatic nucleus or non-aromatic ring part.
Term " cyano group " refers to group-CN.
Term " nitro " refers to group-NO 2.
Term " sulfydryl " refers to group-SH.
Term " alcoxyl carbon back " refers to group-C (=O) OR 6, wherein R 6refer to alkyl.
Term " alkoxyl group " refers to group-OR 7, wherein R 7refer to alkyl.
Term " acyloxy " refers to group-OC (=O) R 8, wherein R 8refer to alkyl.
" optionally " means that subsequently event or the situation described can occur or not occur, described description the parade one's wealth example that wherein said event or situation occur and the example that wherein it does not occur.
" pharmaceutically acceptable carrier " used herein comprise the whole solvent of any core, dispersion medium, dressing, antibacterium and antifungal medicine, etc. blend absorption delay agent etc.Such medium and medicament are well known in the art for pharmaceutically active substances.Unless any conventional media or medicament and activeconstituents are incompatible, expected when its application in therapeutic composition.Supplementary activeconstituents also can be incorporated in composition.
Embodiment 1
(Z) synthesizing of-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-methyl piperidine-4-formyl radical) amino-4-ethoxyl phenenyl) ethene
Step 1: bromination trimethoxy benzyl triphenylphosphine synthetic
3,4,5-Trimethoxybenzaldehyde 4Kg is dissolved in to dehydrated alcohol, stirs, repeatedly add on a small quantity below sodium borohydride 1.4Kg at 35 DEG C.Adding rear reaction spends the night.After having reacted, rotary evaporation is removed ethanol.Add ethyl acetate (10L × 4) extraction, combined ethyl acetate layer, anhydrous magnesium sulfate drying, filters, and pressure reducing and steaming ethyl acetate, obtains 3200ml product.
3,4,5-trimethoxy benzylalcohol 3200ml is dissolved in 20L toluene, stirs, cool to-5-0 DEG C, drip phosphorus tribromide 1L, temperature control is at-5-0 DEG C simultaneously.After being added dropwise to complete, low-temp reaction 2h, returns to room temperature, and reaction is spent the night.
Add purified water 14L termination reaction, stir 30min, separatory, point water-yielding stratum.Organic layer washs Ph value 7.5-8 with saturated sodium bicarbonate solution, and anhydrous magnesium sulfate drying filters, and obtains the toluene solution of trimethoxy benzyl bromine.
In this solution, add triphenyl phosphorus 5.6Kg, more than stirring 48h, have solid to separate out, filter, obtain product crude product, weight in wet base 13Kg.Product dehydrated alcohol recrystallization.
Step 2:(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-amino-4-methoxyl phenyl) ethene synthetic
In chemosynthesis device, under argon shield, bromination trimethoxyphenyl methylene radical triphen Phosphonium 15g (28.7mmol.) is suspended in 300ml THF, be cooled to-15 DEG C of left and right.Splash into the n-Butyl Lithium cyclohexane solution 22ml of 1.6mol/L, react 1 hour.Then,, by 5.7 grams of (29mmol.) 4-oxyethyl group-3-nitrobenzaldehyde 24ml THF solution, be slowly added dropwise in reaction.TLC follows the tracks of, and stirring is spent the night, and temperature of reaction is raised to room temperature.Next day, drops to solution temperature-5 DEG C, adds saturated aqueous common salt stopped reaction.Separate organic layer, except desolventizing.Often pressure column chromatography (silicagel column, 4: 1 n-hexane/ethyl acetate) separate obtain 6.5 grams of pale yellow crystals, be (Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-nitro-4-ethoxyl phenenyl) ethene, productive rate 63%.
In dry 5L four-necked bottle, add 3.5L newly to steam Virahol, dibromo dioctyl dipyridyl 50g, samarium metal powder 120g, finally add (Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-nitro-4-ethoxyl phenenyl) ethene 50g, stir, be heated to reflux.TLC point plate is followed the tracks of, until reaction finishes.After having reacted, suction filtration, concentrated, column chromatography separates, eluent petrol ether/ethyl acetate=4/1.Yield 30～40%.
Step 3:(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-methyl piperidine-4-formyl radical) amino-4-ethoxyl phenenyl) ethene synthetic
1-methyl piperidine-4-formate hydrochlorate (10g, 55.6mmol), adds 100ml thionyl chloride, stirs, and reflux 12h, cooling, pressure reducing and steaming thionyl chloride, obtains off-white color solid.Add the THF that 50ml is dry, solvent evaporated, then repeat this operation 2 times, the solid obtaining is directly used in next step reaction.
Previous step is reacted to the solid obtaining and is dissolved in 100ml pyridine, add amino CA-4(12.2g, 37mmol), stir, be heated to 60 DEG C, reaction 6h.After reaction finishes; reaction solution is poured in 500ml water; add NaOH solution to regulate pH value to 9; there is solid to separate out; filter, the solid obtaining obtains product (Z)-1-(3,4 after post (eluent: chloroform/methanol=9/0.3) is purified; 5-trimethoxyphenyl)-2-(3-(N-methyl piperidine-4-formyl radical) amino-4-ethoxyl phenenyl) ethene 14g, yield 83%.MS(M+1)=455.5。
Embodiment 2
(Z) preparation of-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-methyl piperidine-4-formyl radical) amino-4-ethoxyl phenenyl) ethene Citrate trianion
By (Z)-1-(3; 4; 5-trimethoxyphenyl)-2-(3-(N-methyl piperidine-4-formyl radical) amino-4-ethoxyl phenenyl) ethene 20g joins in 200ml acetone; heating for dissolving; add citric acid 10g; continue reflux 3h, the precipitation that cooled and filtered is separated out, and with obtaining compound shown in title after ethyl alcohol recrystallization.
Utilize different raw materials, by the similar method of embodiment 1, synthesized respectively following various compounds:
Embodiment 31 pharmaceutical preparation formulas
The invention provides the formula of the pharmaceutical composition of several diseases relevant to new vessel paraplasm, its pharmaceutical composition mainly contains the oral preparations such as tablet, capsule.Represent compound shown in the present with " active compound " below.
The anti-tumor activity test of the tumour cell of embodiment 32 to vitro culture
Cell is cultivated with the nutrient solution containing 10% foetal calf serum, makes cell always in logarithmic phase.Cell is inoculated in 96 culture plates, density 4-7 × 10 4/ ml(HUVEC density 3 × 10 4/ ml) .37 DEG C, 5%CO 2the dosing in 24 hours of incubator preculture, medicine is established 6 concentration, and each concentration is established two multiple holes, continuous action 72 hours.After drug effect finishes, use trichoroacetic acid(TCA) fixed cell, after cleaning, add SRB working fluid, after 15min, with 1% acetum washing, with Tris base dissolving and protein bound SRB, under NOCOstar microplate reader 545nm wavelength, measure the OD value of each aperture.Positive control drug is selected CA-4.
According to OD value, calculate inhibitory rate of cell growth.
Inhibiting rate (%)=(control group OD value-medication group OD value)/control group OD value 100
According to the inhibiting rate of medicine cell growth under different concns, calculate IC with Logitech method 50value.
The anti-tumor activity of table 1 active compound to cultured tumor cells in vitro
Note: EACA is compound described in the embodiment of the present invention 1.
Conclusion: compound shown in the present all has obvious anti-tumor activity to the tumour cell of multiple vitro culture; Cell proliferation of human umbilical vein is also had to significant restraining effect; EACA restraining effect is significantly better than positive control CA-4.
The efficacy experiment of embodiment 32 Nude Mice
BALB/cA-nude nude mouse, in 6-7 week, ♀, purchased from Shanghai Slac Experimental Animal Co., Ltd..Subcutaneous Human hepatocarcinoma Bel-7402 cell, colon cancer cell line HT-29, SGC-7901 cell and the Non-small Cell Lung Cancer A 549 inoculated respectively of nude mouse, treats that tumor growth is to 100-250mm 3after, by animal random packet (d0).Survey weekly knurl volume 2-3 time, claim mouse heavy, record data.Gross tumor volume (V) calculation formula is:
V=1/2 × a × b2 wherein a, b represents respectively length and width;
T/C (%)=(T-T0)/(C-C0) × 100 wherein T, C are the gross tumor volume of testing while end;
Gross tumor volume when T0, C0 are experiment beginning.
Institute's test agent is all become to desired concn with 50%PEG400 distilled water diluting.Application method is administration every day 1 time, and gastric infusion, is used in conjunction 21 days.Respectively to embodiment 1,3,4,17, the curative effect of the Nude Mice of compound shown in 23 to people's liver cancer Bel-7402, colon cancer cell line HT-29, SGC-7901 cell and Non-small Cell Lung Cancer A 549 is tested, and its result is as shown in table 2.
The curative effect of the multiple cancer cells Nude Mice of table 2 active compound
Conclusion: compound shown in the present can obviously suppress the growth of people's liver cancer Bel-7402, colon cancer cell line HT-29, SGC-7901 cell and Non-small Cell Lung Cancer A 549 Nude Mice under the condition of gastric infusion.

Claims (10)

1. a general formula II (a) or II (b) represent compound or its pharmacy acceptable salt:
Wherein
R 1methyl, ethyl, difluoromethyl;
R 2hydrogen;
R 4hydrogen, methyl, ethyl, furyl, pyrryl, piperidyl;
R 5independently selected from hydrogen, methyl, amino, carbamyl.
2. compound according to claim 1 or its pharmacy acceptable salt, wherein said compound preferably from:
(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-methyl piperidine-4-formyl radical) amino-4-ethoxyl phenenyl) ethene;
(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-methyl piperidine-4-formyl radical) amino-4-methoxyl phenyl) ethene;
(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(N-methyl piperidine-4-formyl radical) amino-4-difluoro-methoxy phenyl) ethene;
(Z)-1-(3,4,5-trimethoxyphenyl)-2-(3-(pyridine-3-formyl radical) amino-4-methoxyl phenyl) ethene.
3. pharmaceutically acceptable salt of compound according to claim 1 and 2, described salt is and citric acid salify.
4. a pharmaceutical composition, is characterized in that, it contains compound and the pharmaceutically acceptable carrier as described in claim 1-3 any one for the treatment of significant quantity.
5. pharmaceutical composition according to claim 4, pharmaceutically acceptable carrier mainly comprises the thinner that oral preparations uses, lubricant, polyoxyethylene glycol.
6. pharmaceutical composition according to claim 5, pharmaceutically acceptable carrier also comprises disintegrator, sorbent material, dyestuff, seasonings, sweetener.
7. pharmaceutical composition according to claim 5, described oral preparations is tablet.
8. the compound as described in claim 1-3 any one is in the application of preparing in tubulin aggregation inhibitor.
9. the application in the medicine of the disease that the compound as described in claim 1-3 any one causes at the improper new vessel of preparation treatment, the disease that described improper new vessel causes comprises various tumours, mainly contains: lung cancer, liver cancer, carcinoma of the pancreas, cancer of the stomach, osteocarcinoma, esophagus cancer, mastocarcinoma, kidney, cholangiocarcinoma, prostate cancer, carcinoma of testis, colorectal carcinoma, ovarian cancer, bladder cancer, cervical cancer, bronchogenic carcinoma, melanoma, gland cancer, syringocarcinoma, papillary carcinoma, papillary carcinoma, squamous cell carcinoma, rodent cancer, adenocarcinoma cystic, glioma, astrocytoma, medulloblastoma, neuroblastoma, craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, oligodendroglioma, meningioma, neurofibroma, fibrosarcoma, fibroblastoma, fibroma, myxosarcoma, myxocystoma, lipoma, lipoadenoma, chondrosarcoma, chondroma, chondromyoma, chordoma, chorioadenoma, villous vessels knurl, chorioepithelium knurl, chorioblastoma, osteosarcoma, osteoblastoma, osteoclastoma, osteochondrofibroma, osteochondrosarcoma, thigh cystoma, osteodentinoma, osteofibroma, the fibrosarcoma of bone, vascular tumor, angiosarcoma, lymphangiosarcoma, lymphangioma, lymphoma, endothelioma, synovioma, synovial sarcoma, mesothelioma, mesocytoma, ewing's tumor, leiomyoma, leiomyosarcoma, rhabdomyoma, rhabdosarcoma, kemia, acute myelogenous leukemia, chronic leukemia, polycyth(a)emia, multiple myeloma.
10. application according to claim 9, described lung cancer is small cell lung cancer.
CN201310011060.9A 2013-01-11 2013-01-11 Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug Active CN103012248B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201310011060.9A CN103012248B (en) 2013-01-11 2013-01-11 Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug
PCT/CN2014/070286 WO2014108066A1 (en) 2013-01-11 2014-01-08 Synthesis of amino-combretastatin derivatives and use as oral anti-tumour drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201310011060.9A CN103012248B (en) 2013-01-11 2013-01-11 Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug

Publications (2)

Publication Number Publication Date
CN103012248A CN103012248A (en) 2013-04-03
CN103012248B true CN103012248B (en) 2014-11-05

Family

ID=47961411

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201310011060.9A Active CN103012248B (en) 2013-01-11 2013-01-11 Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug

Country Status (2)

Country Link
CN (1) CN103012248B (en)
WO (1) WO2014108066A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103012248B (en) * 2013-01-11 2014-11-05 浙江大德药业集团有限公司 Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug
CN104447598B (en) * 2013-09-18 2017-09-22 浙江大德药业集团有限公司 CA 4 cyclen derivatives and its antitumor properties
US9487482B2 (en) * 2014-05-09 2016-11-08 Council Of Scientific And Industrial Research 3,4,5-trimethoxystyrylarylaminopropenones as potential anticancer agents
CN107365248A (en) * 2017-07-25 2017-11-21 上海应用技术大学 Diphenylethane and trans stilbene derivative of difluoro-methoxy substitution and its preparation method and application
CN112225673B (en) * 2020-11-13 2022-08-02 义乌市华耀医药科技有限公司 Amino combretastatin derivative and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
CN1465580A (en) * 2002-06-07 2004-01-07 深圳市北大高科技股份有限公司 Simple method for synthesizing pro-drug of compete A-4
CN101085743A (en) * 2006-06-06 2007-12-12 浙江大德药业集团有限公司 Fluorine-containing alkoxy combretastatin derivative, preparation method and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) * 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
FR2838437B1 (en) * 2002-04-11 2004-06-04 Aventis Pharma Sa PROCESSES FOR THE PREPARATION OF COMBRETASTATINS
CN102249987B (en) * 2011-05-06 2013-07-24 兰州大学 Combretastatin compound and preparation method and application thereof
WO2013084150A1 (en) * 2011-12-06 2013-06-13 Sanofi Novel crystal form of (2s)-2-amino-3-hydroxy-n-[2-methoxy-2-[(1z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]propanamide and method of preparation thereof
CN103012248B (en) * 2013-01-11 2014-11-05 浙江大德药业集团有限公司 Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430062A (en) * 1992-05-21 1995-07-04 Research Corporation Technologies, Inc. Stilbene derivatives as anticancer agents
US5561122A (en) * 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
CN1465580A (en) * 2002-06-07 2004-01-07 深圳市北大高科技股份有限公司 Simple method for synthesizing pro-drug of compete A-4
CN101085743A (en) * 2006-06-06 2007-12-12 浙江大德药业集团有限公司 Fluorine-containing alkoxy combretastatin derivative, preparation method and use thereof

Also Published As

Publication number Publication date
WO2014108066A1 (en) 2014-07-17
CN103012248A (en) 2013-04-03

Similar Documents

Publication Publication Date Title
CN103012248B (en) Synthesis of amino combretastatin derivative and application of amino combretastatin derivative as oral antitumour drug
US9969695B2 (en) N-substituted imidazole carboxylic ester chiral compound containing an ether side chain, its preparation and application
JP5100749B2 (en) Fluoroalkoxy combretastatin derivative, production method and use thereof
KR20130029380A (en) Sphaelactone derivatives, their pharmaceutical compositions, preparation methods and uses
JP5998139B2 (en) 1,5-diphenyl-penta-1,4-dien-3-one compound
Manon et al. Design, synthesis and evaluation of diclofenac-antioxidant mutual prodrugs as safer NSAIDs
WO2013007184A1 (en) Antineoplastic drug tetrahydronaphthalene amide-group compound and pharmaceutically acceptable salt, preparation method and use thereof
CN111662294A (en) Compound with activity of degrading Btk
CA3218596A1 (en) Psilocybin and psilocin conjugates for treatment of mental illnesses
CN104447598B (en) CA 4 cyclen derivatives and its antitumor properties
CN112225673B (en) Amino combretastatin derivative and application thereof
JP2019509980A (en) Triazole derivative of melanpomagnolide B and method of use thereof
KR101345533B1 (en) Novel adamantine based compound or pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for inhibition of multidrug resistance containing the same as an active ingredient
CN108473449B (en) Sulfonamidine as indoleamine-2, 3-dioxygenase inhibitor and preparation method and application thereof
WO2023123695A1 (en) Dichloroacetic-acid-coupled diphenylethane compound, and preparation method therefor and use thereof
US9751825B2 (en) TAK1 kinase inhibitors, compositions, and used related thereto
US20160102066A1 (en) Benzothiazole derivative and anti-tumor use thereof
JP2001199884A (en) Analgesic agent
KR101532850B1 (en) Benzamide derivative with anticancer activity and preparation method and use thereof
JPS63270663A (en) Alkylcarboxyamides of pyridylalkylamine, manufacture and medicinal composition
WO2022171135A1 (en) Spiro-containing quinazoline derivative
KR20230023661A (en) Selective CDK4/6 Inhibitor Cancer Therapeutics
US8680155B2 (en) Synthesis and antitumor activity of novel bis(benzylidene-benzenamine)disulfides
CN114288299A (en) Antitumor activity and application of LP-211 and derivatives thereof
WO2018167187A1 (en) 5-carboxamide-2-thiobarbituric acids and use thereof as medicaments

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: Synthesis of aminocommutine derivatives and their application as oral antitumor drugs

Effective date of registration: 20220110

Granted publication date: 20141105

Pledgee: Zhejiang Yiwu Rural Commercial Bank Co.,Ltd.

Pledgor: ZHEJIANG DADE PHARMACEUTICAL GROUP Co.,Ltd.

Registration number: Y2022330000037

PC01 Cancellation of the registration of the contract for pledge of patent right
PC01 Cancellation of the registration of the contract for pledge of patent right

Date of cancellation: 20230104

Granted publication date: 20141105

Pledgee: Zhejiang Yiwu Rural Commercial Bank Co.,Ltd.

Pledgor: ZHEJIANG DADE PHARMACEUTICAL GROUP Co.,Ltd.

Registration number: Y2022330000037